June 23, 2026

Astral Systems

Bristol-based Astral Systems raised £23 million in Series A funding to scale production of medical isotopes for cancer diagnosis and treatment using its multi-state fusion reactors, with the goal of bringing Actinium-225 and Lead-212 to market by early 2027.